Unclear Informed Consent Forms May Be a Barrier to Trial Participation
Cody HoltResearch presented during WCLC 2022 shows patient-centered summaries may help potential participants to better understand the benefits and risks of clinical trials. Read more
Get Up to Date on SCLC Brain Metastases, Neuroendocrine Tumors
Fred GebhartExperts evaluate available evidence comparing various strategies, including prophylactic cranial irradiation vs. surveillance, stereotactic radiosurgery vs. whole-brain radiotherapy, and more. Read more
Data Supports Smoking Cessation as Part Active Lung Cancer Treatment
Leah LawrenceExperts reviewed data that show smoking can reduce innate immunity and suppress the efficacy of anti-cancer agents, leading to poorer outcomes for patients who continue to smoke after their cancer diagnosis. Read more
Survey of Women with Lung Cancer Reveals High Levels of Sexual Dysfunction
Cody HoltThe SHAWL study showed most women with lung cancer have little or no interest in sexual activity and experience increased pain and discomfort during sex following their diagnoses. Read more
Advances in radiotherapy, robotic surgery, and artificial intelligence promise to change the practice of thoracic oncology. Read more
Profession challenged to double survival rates within 5 years. Improving screening, reducing barriers to treatments will be key. Read more
Panel Summarizes Immunotherapy Decision-Making for NSCLC
Leah LawrenceDuring a WCLC 2022 education session, experts reviewed the evidence for multiple treatment strategies in various patient populations. Read more
COVID-19 A Roadblock to Effective Lung Cancer Care in 2022
Leah LawrenceA joint session at WCLC explored the impact the pandemic has had on the prevention, diagnosis, and management of thoracic malignancies. Read more
Plenary 4 Panel Examines Applications of Artificial Intelligence in Lung Cancer
John AustinWhile AI and machine learning are not likely to replace humans, ideally technology will enhance and expedite medical decision making. Read more
The term “malignant mesothelioma” is no longer acceptable and should be replaced by “mesothelioma” for all uses, pathology researcher says. Read more